Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 3-17

  Etievant, Chantal ^a   Barret, Jean Marc ^a   Kruczynski, Anna ^a   Perrin, Dominique ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Cross resistance profile; Drug accumulation; Multidrug resistance; P glycoprotein; Vinca alkaloid; Vinflunine

Indexed keywords

GLYCOPROTEIN P; UNCLASSIFIED DRUG; VINCA ALKALOID; VINFLUNINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CROSS RESISTANCE; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALCIUM CHANNEL BLOCKERS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA P388; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; P-GLYCOPROTEIN; PHENOTYPE; TUMOR CELLS, CULTURED; VERAPAMIL; VINBLASTINE;

EID: 0031820395     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006022811895     Document Type: Article

References (64)

1. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT: Preclinical in vivo antitumour activity of vinflumine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41:437-447, 1998
2. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy I, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55:635-648, 1998
3. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277-286, 1991
4. Hill BT: Differing patterns of cross-resistance resulting from exposure to specific antitumour drugs or to radiation in vitro. Cytotechnology 12:265-288, 1993
5. Hill BT, Whelan RD, Shellard SA, McLean S, Hosking L: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169-182, 1994
6. Beck WT: Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 17:11-20, 1990
7. Murren JR, Hait WN: Why haven't we cured multidrug resistant tumors? Oncol Res 4:1-6, 1992
8. Aftab DT, Yang JM, Hait WN: Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug resistant MCF-7 cells. Oncol Res 26:69-70, 1994
9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Med 62:385-427, 1993
10. Pinedo HM: Drug resistance, illustration of the complexity of translational research. Steiner Award Lecture. Int J Cancer 65:561-566, 1996
11. Mirski SE, Gerlach JH, Cole SPC: Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res 47:2594-2598, 1987
12. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SE: Non-P-glycoprotein-mediated multidrug resistance in a small cell lung carcinoma cell line: Evidence for decreased susceptibility to drag-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51:3345-3352, 1991
13. Cole SPC, Bhardwaj G, Gerlach JH, Machie JE, Grant CE, Almquist KC, Stewart AJ, Kurts EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 258:1650-1654, 1992
14. Zaman GJR, Versantwoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mudler NH, de Vries EGE, Baas F, Borst P: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant cancer cell lines. Cancer Res 53:1747-1750, 1993
15. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR: A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86:110-117, 1994
16. Adams DJ, Knick VC: P-glycoprotein mediated resistance to (5′-nor-anhydro-vinblastine (Navelbine®). Invest New Drugs 13:13-21, 1995
17. Fahy J, Duflos A, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP, Zunino F: Vinca-alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119:8576-8577, 1997
18. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, Wallace J, Straughan DW: UKCCCR guidelines for the welfare of animals in experimental neoplasia. Laboratory Animals 22:195-201, 1988
19. Venditti JM: Preclinical drug development; rationale and methods. Semin Oncol 8:349-361, 1981
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
21. Habig WH, PabstMJ, Jakoby WB: Glutathione S-transferases. J Biol Chem 219:7130-7139, 1974
22. Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2 vinyl pyridine. Anal Biochem 106:207-212, 1980
23. Bradford MM: A rapid and sensitive method for the quantifcation of microgram quantity of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
24. Johnson RK, Chitnis MP, Embrey WM, Gregory EB: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535-1547, 1978
25. Kartner N, Everden-Porelle D, Bradley G, Ling V: Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823, 1985
26. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT: Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869, 1988
27. Cowan KH, Batist G, Tulpule A, Sinha B, Myers CE: Similar biochemical changes in human breast cancer cells and carcinogen-induced resistance to xenobiotics. Proc Natl Acad Sci USA 83:9328-9332, 1986
28. Pauwels O, Kiss R: Digital morphnuclear analysis of sensitive versus resistant neoplastic cells to Vinca-alkaloid, alkylating, and intercalating drugs. Cytometry 12:388-397, 1991
29. De Jong S, Zijlstra JG, de Vries EGG, Mudler NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in extracts from a human small cell lung carcinoma cell line. Cancer Res 50:304-309, 1990
30. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R: Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 44:937-945, 1992
31. Chen G, Waxman DJ: Complete reversal by Thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug-resistance. J Pharmacol Expt Therapeut 274:1271-1277, 1995
32. Labarre JF: Natural polyamines-linked cyclophosphazenes: attempts at the production of more selective antitumourals. Topic Curr Chem 129:173-260, 1985
33. Etievant C, Pauwels O, Kiss R: Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines. J Cancer Res Clin Oncol 120:76-84, 1993
34. Hipfner D, Gauldie SD, Deeley RG, Cole SPC: Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792, 1994
35. 4 sub-lines with increasing adriamycin resistance. Int J Cancer 61:375-380, 1995
36. Mosman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method 65:55-63, 1983
37. Kramer RA, Zakher J, Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241:694-697, 1988
38. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 48:3595-3602, 1988
39. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A:991-1001, 1996
40. Creasey WA, Markiw MM: Biochemical effects of the Vinca alkaloids III. The synthesis of ribonucleic acid and the incorporation of amino acids in Ehrlich ascites cells in vitro. Biochim Biophys Acta 103:635-645, 1965
41. Owellen RJ, Donigian DW, Hartke CA, Hains FO: Correlation of biologic data with physicochemical properties among the Vinca alkaloids and their congeners. Biochem Pharmacol 26:1213-1219, 1977
42. Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA: Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413-429, 1992
43. Fichtner I, Stein U, Hoffmann J, Winterfield G, Pfeil D, Hentschel M: Characterisation of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity. Anticancer Res 14:1995-2004, 1994
44. Tang-Wai DF, Brossi A, Arnold LD, Gros P: The nitrogen of the acetamido group of cochicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 32:6470-6476, 1993
45. Ringel I, Jaffe D, Alerhand S, Boye O, Muzaffar A, Brossi A: Fluorinated colchicinoids: antitubulin and cytotoxic properties. J Med Chem 34:3334-3338, 1991
46. Judson I, Briasoulis E, Raynaud F, Hanwell J, Berry C, Lacey H: Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85 - a synthetic agent binding at the cochicine site designed to overcome multidrug resistance. Br J Cancer 75(4):608-613, 1997
47. Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC: Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3:401-407, 1997
48. Inaba M, Fujikura R, Sakurai Y: Comparative study on in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Gann 70:607-613, 1979
49. Hill BTH, Whelan RDH: Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drag sensitivities. Cancer Chemother Pharmacol 8:163-169, 1982
50. Nielsen D, Skovsgaard T: P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1139:169-183, 1992
51. Kaye SB: Reversal of multidrug resistance. Cancer Treat Rev 18:37-43, 1990
52. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1994
53. Tsuruo T, Tomida A: Multidrug resistance. Anti-Cancer Drugs 6:213-218, 1995
54. Lautier D, Canitrot Y, Deeley RG, Cole SPC: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967-977, 1996
55. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F, Brost P: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Nat Acad Sci USA 92:7690-7694, 1995
56. 4 and chemotherapeutic agents in membrane vesicules: demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682, 1996
57. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R: Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 74:888-896, 1996
58. Gottesman MM: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 53:747-754, 1993
59. Colin M, Madoulet C, Warren L, Jardillier JC: Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells. Anticancer Res 16:407-412, 1996
60. Zhou XJ, Rhamani R: Preclinical and clinical pharmacology of Vinca alkaloids. Drugs 44:1-16, 1992
61. Houghton JA, Houghton PJ, Hazelton BJ, Douglas EC: In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45:2706-2712, 1985
62. Cabral F, Barlow SB: Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593-1599, 1989
63. Jafrézou JP, Dumontet C, Deny WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sisik BI: Novel mechanism of resistance to paclitaxel (Taxol®) in human K562 leukemia cells by combined selection with PSC 833. Oncology Res 7:517-527, 1995
64. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921-926, 1996